Intra-myocardial injection of Angiopoietin-1 plasmid inhibits cardiomyocyte apoptosis and improves cardiac function in rats with acute myocardial infarction

Zuo-yan Wang,Li-jie Sun,Ming Cui,Xin-heng Feng,Chun-yan Zhou,Feng-rong Chen

DOI: https://doi.org/10.3321/j.issn:1673-8225.2006.36.034

2006-01-01

Abstract:AIM: To observe the effects of intra-myocardial injection of plasmid angiopoietin-1 gene on myocardial cell apoptosis in rats with acute myocardial infarction, and further probe into the effects of angiopoietin-1 gene treatment on the remodeling of ventricles in rats with acute myocardial infarction. METHODS: The experiment was conducted in the Laboratory of Biochemistry and Molecular Biology, Medical Department of Peking University from September 2004 to September 2005.①Ninety-five SD male rats of SPF inbred strain aged 6 weeks old with the body mass of (250 ±26)g were selected and randomly divided into 4 groups: sham-operation group (n=20), model group (n=28), vector treatment group (n=24), gene treatment group (n=23).②Rats were ligated of the left anterior descending artery to made into acute myocardial infarction models. Sham-operation group: Rats were braided of the left anterior descending artery without ligation. Rats in the model group were injected with phosphate buffered solution at multiple points in the periphery of infarction tissues after model-establishment. Rats in the carrier treatment group were injected with 50 μg of vector plasmid at multiple points in the periphery of infarction tissues after model-establishment. Rats in the gene treatment group were injected with 50μg of angiopoietin-1 plasmid at multiple points in the periphery of infarction tissues after model establishment.③At 3, 7, 14, 28 days after operation, rats were examined by echocardiography. The polymerase chain reaction was used to semiquantitatively analyze the exogenous angiopoietin-1 mRNA and expression of mRNA in protein kinase B. The apoptosis of cardiomyocyte were studied by DNA segmental in situ end labeling method.④The differences of measurement data were compared with single-factor analysis of variance. RESULTS: Fifteen rats withdrew from the experiment for death and others, and there were totally 80 rats involved in the analysis of results with 5 rats in each group at the detecting time-point.①The expressions of exogenous angiopoietin-1 mRNA in myocardial tissues: no expression was found in rats of sham-operation group, model group, carrier treatment group at 3, 7, 14 and 28 days after operation, while there were expressions in the gene treatment group, which was in a high level, and it could be found at 28 days after injection.②The number of apoptosis of cardiomyocyte: at 3, 7, 14 and 28 days after operation, it was significantly less in the gene treatment group than that in the model group and carrier treatment group (P < 0.05).③Expression of protein kinase B mRNA in the myocardial tissues: it was remarkably higher in the gene treatment group than that in the model group and carrier treatment group at 3, 7, 14, 28 days after operation (P < 0.01), while there was no marked differences between the model group and carrier treatment group (P > 0.05).④Cardiac function: The dilation in left ventricle were obviously attenuated in the gene treatment group than that in the model group and vector treatment group at 7, 14 and 28 days after operation (P < 0.05). At 3, 7, 14 and 28 days after operation, the ejection fraction and shortening fraction were remarkably lower in the model group and carrier treatment group than those in the sham-operation group (P < 0.01), while those in the gene treatment group at 7, 14 and 28 days after operation were obviously higher than those in the model group and carrier treatment group (P < 0.05). CONCLUSION: Intra-myocardial injection of Angiopoietin-1 plasmid may inhibit the apoptosis of cardiomyocyte in myocardial infarction, improve the survival of cardiomyocyte and ameliorate the ventricular remodeling of ventricle as well as the progress of heart failure after acute myocardial infarction by activating the signal transduction pathway of protein kinase B.